Exscientia to Present at Upcoming Investor Conferences in June

Exscientia (Nasdaq: EXAI) has announced its participation in two significant investor conferences in June 2024.

(Neutral)

(Neutral)How Sentiment works

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

How Sentiment works How the balance works

Tags

conferences

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

05/30/2024 - 07:00 AM

OXFORD, England--(BUSINESS WIRE)-- Exscientia plc (Nasdaq: EXAI) today announced that members of Exscientia management will participate in the following upcoming investor conferences in June:

Barclays Digital and Disruptive Technology Conference. Panel on Tuesday, June 11, 2024 at 9:45 a.m. BST in London, England
Goldman Sachs 45^th Annual Global Healthcare Conference. Fireside chat on Tuesday, June 11, 2024 at 3:20 p.m. EDT (8:20 p.m. BST) in Miami, Florida

Live webcasts of the Barclays and Goldman Sachs events will be available on the Company’s website, under the “Investors & Media” section at www.investors.exscientia.ai. Archived replays of the webcasts will be available for approximately 30 days following the presentation.

About Exscientia

Exscientia is an AI-driven precision medicine company committed to discovering, designing and developing the best possible drugs in the fastest and most effective manner. Exscientia developed the first-ever functional precision oncology platform to successfully guide treatment selection and improve patient outcomes in a prospective interventional clinical study, as well as to progress AI-designed small molecules into the clinical setting. Our internal pipeline is focused on leveraging our precision medicine platform in oncology, while our partnered pipeline broadens our approach to other therapeutic areas. By pioneering a new approach to medicine creation, we believe the best ideas of science can rapidly become the best medicines for patients.

For more information visit us on www.exscientia.ai or follow us on LinkedIn @ex-scientia and X @exscientiaAI.